Amincewa da Jiyya don Maimaituwa da Mai Rarraba Multiple Myeloma

A Ostiraliya kusan mutane 2,400 ana bincikar su kowace shekara tare da myeloma da yawa (MM), kuma kusan marasa lafiya 20,000 suna rayuwa tare da MM a kowane lokaci. Abin takaici, fiye da marasa lafiya 1000 za su mutu daga wannan nau'in ciwon daji na jini a kowace shekara kuma saboda haka ana buƙatar sababbin hanyoyin magani kamar XPOVIO®.              

Antengene Corporation Limited a yau ta sanar da cewa Hukumar Kula da Kaya (TGA) na Ma'aikatar Lafiya ta Gwamnatin Ostiraliya ta yi rajistar XPOVIO® (selinexor) don alamu guda biyu: (1) A hade tare da bortezomib da dexamethasone (XBd) don kula da tsofaffi marasa lafiya tare da Multi myeloma (MM) waɗanda suka sami aƙalla magani guda ɗaya da (2) a hade tare da dexamethasone (Xd) don kula da marasa lafiya na manya tare da sake dawowa da / ko refractory multiple myeloma (R / R MM) waɗanda suka karɓi aƙalla uku. kafin hanyoyin kwantar da hankali kuma wanda cutar ta kasance mai ƙin yarda ga aƙalla mai hana proteasome (PI), aƙalla samfurin magani na rigakafi guda ɗaya (IMiD), da anti-CD38 monoclonal antibody (mAb).

XPOVIO® shine na farko kuma kawai SINE da TGA ta amince da ita wanda ke taimakawa wajen dawo da hanyoyin kawar da ƙari na jiki.

Farfesa Hang Quach, masanin ilimin jini a Asibitin St Vincent, Melbourne, yayi sharhi, “Na sami damar kasancewa ɗaya daga cikin masu bincike a cikin binciken asibiti na BOSTON kuma tun daga lokacin na yi haɗin gwiwa kan wasu takardu kan tsarin XBd. Wannan tsarin tsarin sau uku ba shakka a cikin raina yana cikin mafi inganci hanyoyin warkewa don komawa da wuri a zamanin lenalidomide refractoriness. A kan nazarin juzu'i, wannan tsarin sau uku yana da tasiri ba tare da la'akari da shekaru, marasa ƙarfi ko marasa rauni ba kuma yana da tasiri a cikin marasa lafiya da ƙarancin creatinine. Mahimmanci, haɗin XBd yana da tasiri musamman a cikin marasa lafiya masu haɗarin cytogenetics.

Farfesa Hang Quach ya ci gaba da yin sharhi "Na yi imani cewa layukan farko na farko na MM guda uku sune mafi mahimmanci wajen daidaita rayuwar majiyyaci gaba ɗaya saboda yawancin marasa lafiya tare da MM a cikin yanayin duniyar ba za su rayu don ganin layin na huɗu na jiyya ba ko bayan. Bugu da ƙari, ana samun mafi girman fa'idar asibiti lokacin da aka yi amfani da ingantaccen magani a cikin koma bayan layin farko. Don haka yana da mahimmanci a bai wa likitan isasshen zaɓi a cikin “layi ɗaya zuwa uku da suka gabata” don ba da damar yin amfani da mafi kyawun tsarin da ya dogara akan bayanan asibiti na majiyyaci. Rashin isassun zaɓuɓɓuka don majinyata na lenalidomide-refractory a farkon layin dawowar MM yanki ne na buƙatu da ba a cika buƙata ba a Ostiraliya. Samuwar XPOVIO®, bortezomib da dexamethasone a matsayin zaɓi a cikin wannan sarari zai magance wannan buƙatar da ba ta cika ba."

"A Ostiraliya, wani yanki mai mahimmanci na rashin biyan buƙatun marasa lafiya tare da myeloma shine rashin ingantattun hanyoyin kwantar da hankali ga marasa lafiya waɗanda ke da juzu'i uku, wanda ke da alaƙa da mai hana proteasome, maganin rigakafi da rigakafin CD38 monoclonal antibody. Amfanin XPOVIO® shine cewa maganin baka ne tare da sabon tsarin aiki wanda ya sa ya dace da marasa lafiya masu jujjuya aji uku. XPOVIO® na iya haifar da martani da kuma tsawaita rayuwa ta hanya mai ma'ana ta asibiti", in ji Farfesa Andrew Spencer, Masanin ilimin jini, Asibitin Alfred, Melbourne.

Hayley Beer, Shugaban riko na Myeloma Ostiraliya, ya ce "Yana da matukar muhimmanci a sami wani zaɓi na magani ga mutanen da ke zaune tare da myeloma da yawa, a cikin layin farko da na gaba na jiyya. XPOVIO® sabon nau'in magani ne tare da yanayin aiki na musamman, don haka yana nufin cewa majiyyata za su iya gwada sabon haɗin gwiwa ba tare da sun sake yin amfani da wani nau'in magungunan da aka yi amfani da su a baya ba."

"Wannan wani muhimmin ci gaba ne ga Antengene da kuma ga marasa lafiya na MM a Ostiraliya. Mun yi matukar farin ciki da ƙaddamar da XPOVIO® da kawo wa likitocin Australiya da marasa lafiya wani labari ƙari ga tsarin da suke da shi don maganin R/R MM. Kamar yadda samfurinmu na farko da za a yi rajista a Ostiraliya, yana kuma nuna alamar juyin halitta na Antengene a Ostiraliya zuwa ƙungiyar biopharmaceutical tare da alƙawarin ci gaba da ci gaba da sayar da magungunan canji don ciwon daji da sauran cututtuka masu barazana ga rayuwa a Australia, "in ji Thomas Karalis. CVP Asia Pacific na Antengene.

“Jerin yarda da aka baiwa XPOVIO® a China, Koriya ta Kudu, Singapore da kuma Australiya a cikin watanni shida da suka gabata sun nuna babban tasirin maganin. A Ostiraliya, akwai kusan mutane 2,400 da aka gano na MM kowace shekara, don haka suna gabatar da buƙatu na gaggawa na asibiti a cikin kula da MM,” in ji Jay Mei, Wanda ya kafa Antengene, Shugaba da Shugaba. "Wannan amincewar da TGA ta yi shine canjin aiki ga marasa lafiya a Ostiraliya waɗanda suka daɗe suna fama da MM. Mun himmatu wajen kawo sabbin magunguna da hanyoyin kwantar da hankali ga marasa lafiya da ke fama da cutar kansa ko wasu cututtukan da ke barazana ga rayuwa a yankin Asiya Pacific da ma duniya baki daya. Yanzu, ƙungiyar kasuwancinmu ta shirya sosai don ƙara faɗaɗa damar marasa lafiya zuwa wannan sabon jigon, ginawa bisa ƙwarewar kasuwancinmu tare da ƙaddamar da XPOVIO® a China, Singapore da Koriya ta Kudu."